Drug intelligence / Profile preview

whole cell killed cholera vaccine + probiotic

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

This is a combination product consisting of a whole cell killed oral cholera vaccine (kOCV) and a probiotic. The kOCV component contains inactivated (killed) Vibrio cholerae whole cells, typically from both O1 and O139 serogroups, designed to induce protective immunity against cholera by stimulating the intestinal immune response and limiting V. cholerae colonization of the gut[2][3][6]. Probiotics are live microorganisms that confer health benefits to the host, often by modulating gut microbiota or enhancing mucosal immunity. The rationale for combining these agents is based on evidence that certain probiotics or their metabolites (such as short-chain fatty acids like butyrate) can enhance mucosal immune responses induced by oral vaccines, potentially improving efficacy or speed of protection[5]. This combination aims to provide both direct immunological protection against cholera and additional support for gut health and immune modulation.

Targets

TLR2 (Toll-like Receptor 2)NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)HCAR2 (Hydroxycarboxylic acid receptor 2)

Beyond the preview

Go deeper on whole cell killed cholera vaccine + probiotic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on whole cell killed cholera vaccine + probiotic.

Explore the full profile